Gut Microbiome AI Diagnostic Platform MicrobiomeAI Launches: One Stool Sample Screens 15 Digestive Diseases
Digestive health company GutInsight launches MicrobiomeAI, a gut microbiome diagnostic platform where users collect stool samples via home kits and send them to the lab, with AI analysis through metagenomic sequencing and metabolomics delivering screening reports covering 15 digestive diseases within 72 hours.
Gut Microbiome AI Diagnostic Platform MicrobiomeAI Launches
Digestive health company GutInsight launched its gut microbiome AI diagnostic platform MicrobiomeAI on September 1. Users collect stool samples using home collection kits and mail them to the lab, where the system completes metagenomic sequencing and metabolomics analysis within 72 hours, generating screening reports covering 15 digestive diseases including inflammatory bowel disease, irritable bowel syndrome, and early colorectal cancer indicators.
MicrobiomeAI's analysis model is trained on over 500,000 gut microbiome samples, capable of identifying abnormal patterns in microbiome diversity, key bacterial species ratios, and metabolite profiles. A single test costs approximately $299, and GutInsight has established retail partnerships with CVS and Walgreens.
Disclaimer
Content is AI-generated. Do not use it as a basis for real decisions. Do not cite it as factual reporting.